NEW YORK (GenomeWeb News) – Bio-Matrix Scientific Group has signed a letter of intent with the genetic analysis and anti-aging specialty company Vibragene, under which it will negotiate an agreement to supply genetic testing for certain disease biomarkers.
 
Bio-Matrix said that Vibragene expects to send it 100,000 specimens during the next 12 months. The firm also said that the addition of the DNA testing capabilities complements its current business lines of processing and storing stem cells for future medical use.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.